5-Jun-2026
AbCellera Biologics Adds Victor Sandor to Board
TipRanks (Fri, 5-Jun 12:30 PM ET)
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
Business Wire (Fri, 5-Jun 9:00 AM ET)
Market Chameleon (Tue, 12-May 3:11 AM ET)
Business Wire (Mon, 11-May 4:05 PM ET)
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
Business Wire (Thu, 7-May 4:05 PM ET)
Business Wire (Mon, 20-Apr 9:00 AM ET)
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
Business Wire (Wed, 1-Apr 4:05 PM ET)
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Abcellera Biologics - Common Shares trades on the NASDAQ stock market under the symbol ABCL.
As of June 5, 2026, ABCL stock price declined to $5.62 with 8,069,235 million shares trading.
ABCL has a beta of 3.30, meaning it tends to be more sensitive to market movements. ABCL has a correlation of 0.23 to the broad based SPY ETF.
ABCL has a market cap of $1.72 billion. This is considered a Small Cap stock.
Last quarter Abcellera Biologics - Common Shares reported $8 million in Revenue and -$.14 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.06.
In the last 3 years, ABCL traded as high as $8.05 and as low as $1.89.
The top ETF exchange traded funds that ABCL belongs to (by Net Assets): IBB, SPDW, IDNA, GWX, ONEQ.
ABCL has outperformed the market in the last year with a price return of +137.1% while the SPY ETF gained +25.6%. ABCL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +56.5% and +8.1%, respectively, while the SPY returned +8.5% and -1.1%, respectively.
ABCL support price is $5.92 and resistance is $6.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABCL shares will trade within this expected range on the day.